Regular Article
Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants

https://doi.org/10.1053/beha.1999.0056Get rights and content

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect, being present in over 400 million people world wide. In a small number of cases, G6PD deficiency can lead to mild-to-severe chronic haemolysis, which is further exacerbated by oxidative stress. Such G6PD variants have been described all over the world and are responsible for chronic non-spherocytic haemolytic anaemia (CNSHA). To date 61 G6PD molecular variants associated with CNSHA have been identified, only some of which can cause the severe reduction in stability of the red blood cell enzyme. The distribution of the different mutations shows a predominance of small mutational events, and many have been found repeatedly in different parts of the world. By revisiting the 61 class I variants described so far, we can observe that a low inhibition constant (Ki) for NADPH, a higher Kmfor substrates and a reduced thermostability are common.

References (99)

  • S Zimmerman et al.

    A de novo mutation associated with chronic hemolytic anemia

    Journal of Pediatry

    (1997)
  • W Xu et al.

    Glucose-6 phosphate dehydrogenase mutations and haplotypes in various ethnic groups

    Blood

    (1995)
  • A Hirono et al.

    G6PD Nara: a new class 1 glucose-6-phosphate dehydrogenase variant with an eight amino acid deletion

    Blood

    (1993)
  • E Beutler et al.

    Three new exon 10 glucose-6-phosphate dehydrogenase mutations

    Blood Cells, Molecules and Diseases

    (1995)
  • E Beutler et al.

    Biochemical variants of glucose-6-phosphate dehydrogenase giving rise to congenital nonspherocytic hemolytic disease

    Blood

    (1968)
  • MD Cappellini et al.

    Different origin of nt 1246 glucose-6-phosphate dehydrogenase mutation

    Blood

    (1994)
  • P Rowland et al.

    The three-dimensional structure of G6PD from Leuconostoc mesenteroides refined at 2·0 Å resolution

    Structure

    (1994)
  • A Yoshida et al.

    Regulation of glucose-6-phosphate dehydrogenase activity in red blood cells from hemolytic and nonhemolytic variant subjects

    Blood

    (1973)
  • S Miwa et al.

    Glucose-6-phosphate dehydrogenase variants in Japan

  • J Yuan et al.

    Isolation, characterization and immunoprecipitation studies of immune complexes from membranes of β-thalassemic erythrocytes

    Blood

    (1992)
  • DR Miller et al.

    A new variant of glucose-6-phosphate dehydrogenase deficiency hereditary hemolytic anemia: G6PD Cornell: erythrocyte, leukocyte, and platelet studies

    Blood

    (1974)
  • GJ Johnson et al.

    G-6-PD Long Prairie: a new mutant exhibiting sensitivity to inhibition by NADPH and accompanied by nonspherocytic hemolytic anemia

    Blood

    (1977)
  • MC Rattazzi et al.

    G6PD deficiency and chronic hemolysis: four new mutants—relationships between clinical syndrome and enzyme kinetics

    Blood

    (1971)
  • M Hafez et al.

    Improved erythrocyte survival with combined vitamin E and selenium therapy in children with glucose-6-phosphate dehydrogenase deficiency and mild chronic haemolysis

    Journal of Pediatrics

    (1986)
  • L Luzzatto et al.

    Glucose-6-phosphate dehydrogenase deficiency

  • PJ Mason

    New insights into G6PD deficiency

    British Journal of Haematology

    (1996)
  • MS Cosgrove et al.

    On the mechanism of the reaction catalyzed by glucose 6-phosphate dehydrogenase

    Biochemistry

    (1998)
  • Bulletin of the World Health Organization

    (1989)
  • K Betke et al.

    Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO scientific group

    WHO Technical Report Series

    (1967)
  • E Beutler et al.

    International Committee for Standardization in Haematology. Recommended methods for red cell enzyme analysis

    British Journal of Haematology

    (1977)
  • E Beutler

    Genetics of glucose-6-phosphate dehydrogenase deficiency

    Seminars in Hematology

    (1990)
  • TJ Vulliamy et al.

    Clinical and haematological consequences of recurrent G6PD mutations and a single new mutation causing chronic nonspherocytic haemolytic anaemia

    British Journal of Haematology

    (1998)
  • A Hirono et al.

    Molecular analysis of glucose-6-phosphate dehydrogenase variants in the Solomon Islands

    American Journal of Human Genetics

    (1995)
  • D MacDonald et al.

    Deficiency in red blood cells

    Nature

    (1991)
  • M Maeda et al.

    Molecular abnormalities of a human glucose-6-phosphate dehydrogenase variant associated with undetectable enzyme activity and immunologically cross-reacting material

    American Journal of Human Genetics

    (1992)
  • R Zarza et al.

    Two new mutations of the glucose-6-phosphate dehydrogenase (G6PD) gene associated with haemolytic anaemia: clinical, biochemical and molecular relationships

    British Journal of Haematology

    (1997)
  • JL Vives-Corrons et al.

    Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction and increased susceptibility to infections. Description of a new molecular variant (G6PD Barcelona)

    Blood

    (1982)
  • Khan, P, M, Ploem, J, E, Wijnen, J, T, G6PD Volendam: de novo mutation of unusual mechanism in a severely deficient...
  • H Ogura et al.

    A new glucose-6-phosphate dehydrogenase variant (G6PD Tsukui) associated with congenital hemolytic anemia

    Human Genetics

    (1988)
  • E Beutler

    G-6-PD: historical perspective and current status

  • E Beutler et al.

    Definition of the mutations of G6PD Wayne, G6PD Viangchan, G6PD Jammu and G6PD ‘LeJeune’

    Acta Haematologica (Basel)

    (1991)
  • V Poggi et al.

    DNA sequence abnormalities of human glucose-6-phosphate dehydrogenase gene by PCR amplification of the entire coding region from genomic DNA

    Biochemical Journal

    (1990)
  • T Takizawa et al.

    A unique electrophoretic slow-moving glucose 6-phosphate dehydrogenase variant (G6PD Asahikawa) with a markedly acidic pH optimum

    Human Genetics

    (1984)
  • Y Ravindranath et al.

    Two new variants of glucose-6-phosphate dehydrogenase associated with congenital non-spherocytic hemolytic anemia: G6PD Wayne and G6PD Huron

    American Journal of Hematology

    (1987)
  • SJ Corey et al.

    Clinical, genetic, and biochemical features of G-6PD West Virginia

    American Journal of Hematology

    (1996)
  • A Hirono et al.

    Identification of the binding domain for NADP+ of human G6PD by sequence analysis of mutants

    Proceedings of the National Academy of Sciences of the USA

    (1989)
  • A Rovira et al.

    Molecular genetics of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Spain: identification of two new point mutations in the G6PD gene

    British Journal of Haematology

    (1995)
  • E Beutler et al.

    G-6-PD WalterReed: possible insight into ‘structural’ NADP in G-6-PD

    American Journal of Hematology

    (1986)
  • E Beutler et al.

    Genetic variation of glucose-6-phosphate dehydrogenase: a catalog and future prospects

    Medicine (Baltimore)

    (1988)
  • Cited by (53)

    • Glucose-6-Phosphate Dehydrogenase Deficiency

      2016, Hematology/Oncology Clinics of North America
      Citation Excerpt :

      For the rare cases of CNSHA that are associated with G6PD deficiency, the management is different from that discussed previously; it is more similar to that of CNSHA related to other causes (eg, hereditary spherocytosis and pyruvate kinase deficiency). This specialized topic is discussed in other reviews.15,78 Knocking out G6PD in mouse embryonic stem cells revealed that the cells were viable, but transfer into blastocysts has proved that a G6PD-null mutation is lethal in embryonic life24; this explains why G6PD-null mutations are never found in humans and also proves conclusively that the irreplaceable function of G6PD is not pentose synthesis but defense against oxidative stress.79,80

    • G6PD Deficiency. Global Distribution, Genetic Variants and Primaquine Therapy

      2013, Advances in Parasitology
      Citation Excerpt :

      For example, many of the most severe mutations map to exon 10 (Mehta et al., 2000) which encodes the binding interface of the subunits and therefore disrupt its quaternary structure and stability. These mutations cause the most severe clinical symptoms and as such do not reach polymorphic frequencies; instead they usually result from independent spontaneous mutations (Fiorelli et al., 2000). Mutations which do not cause such severe reductions in enzyme activity are widely distributed across the gene’s coding region and throughout the enzyme structure (Fig. 4.2), and have been found to reduce the efficacy of protein folding, for example (Gomez-Gallego et al. (1996)).

    View all citing articles on Scopus
    View full text